RxDoctor Payments Data

Janet Dubeck, MD

Internal Medicine · Troy, MINPI 1033170022

Payments from drug & device makers

$3,523in general payments, 2019–2025

Across 52 payments — averaging $67.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Novo Nordisk$653
  • AstraZeneca$487
  • GSK$251
  • Pfizer$162
  • Johnson & Johnson$158
  • plus $728 from 8 others

What the payments were for

  • Food & beverage$3,523100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,523 in reported general payments places this provider in the 85th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$338,187
Medicare patients
275
Services billed
10,599

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin33$37,712
EliquisApixaban38$36,511
JanuviaSitagliptin Phosphate21$26,188
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$14,217
SynthroidLevothyroxine Sodium65$6,880
Sumatriptan Succinate23$4,418
Rosuvastatin Calcium232$3,958
Atorvastatin Calcium349$3,850
Ezetimibe96$3,799
Losartan Potassium248$3,622
Pulmicort FlexhalerBudesonide12$3,512
Levothyroxine Sodium246$3,202
Boostrix TdapDiphth,pertuss(Acell),tet Vac44$3,169
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$2,820
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$2,807

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$122$37,71233 claims
PfizerEliquis$162$36,51138 claims
MerckJanuvia$61$26,18821 claims
GSKTrelegy Ellipta$251$14,21722 claims
AbbVieSynthroid$125$6,88065 claims
AstraZenecaPulmicort Flexhaler$487$3,51212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Troy

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →